Form 4: BioCryst Pharmaceuticals Director, Vincent Milano, Reports Stock and Option Grants

Director Vincent Milano reported the acquisition of common stock and stock options from BioCryst Pharmaceuticals on June 12, 2024, as part of a non-employee director compensation policy.

Summary

• On June 12, 2024, Vincent Milano, a director of BioCryst Pharmaceuticals, reported acquiring 6,820 shares of common stock and 49,933 stock options.
• The common stock was received as an automatic non-employee director grant of Restricted Stock Units, which will vest on the first anniversary of the grant date.
• The stock options were also granted automatically under the company's Non-Employee Director Compensation Policy.
• The exercise price for the options is $6.30, and they become exercisable on June 12, 2025, expiring on June 12, 2034.
• Following the reported transaction, Milano directly owns 74,687 shares of BioCryst Pharmaceuticals.
• Milano also owns 49,933 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects standard director compensation practices, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grants of stock and options to a director align the director's interests with those of the shareholders.
• The vesting schedule for the Restricted Stock Units encourages the director's continued service with the company.

Industry Context

Director compensation through stock and options is a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice across the pharmaceutical industry.
• Companies like Amgen and Gilead Sciences also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and exercise prices are generally in line with industry norms, aiming to incentivize long-term value creation.

Stakeholder Impact

• The stock and option grants align the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholders.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates